Food Exec Brief: Tariff Whiplash, Reformulation Pressure, and the GLP-1 Mandate

This week’s Food Exec Brief covers the Supreme Court’s landmark tariff ruling and the rapid workaround, a reformulation race triggered by the FDA’s updated “healthy” definition, and the food industry’s full-court press to adapt to GLP-1-driven demand shifts before they become existential.

Key takeaways:

• 💰 Big Food’s reinvention race is on: Kraft Heinz leans on operational blueprints to execute its $600M turnaround while the broader industry faces a bifurcated recovery. Scale players are investing aggressively, and mid-tier companies are struggling to keep pace.
• ⚖️ Regulatory pressure compounds from multiple directions: The FDA’s updated “healthy” definition is triggering a sourcing scramble ahead of 2028, California tightens ingredient oversight with national implications, and the FSMA 204 compliance window officially resets to July 2028.
• ⛓️ Tariff certainty evaporates, again: The Supreme Court strikes down IEEPA tariffs 6-3, but they’re immediately replaced with a 10% global levy under different authority, and McCormick warns the era of absorbing cost is over.
• 🤖 AI hits a data wall for mid-sized manufacturers: The biggest barrier to AI ROI isn’t the algorithm, but fragmented legacy data infrastructure that makes implementation fail before it starts.
• 🏪 GLP-1 adoption crosses the point of no return: About 1 in 8 U.S. adults now uses these drugs, grocery spending in affected households is down 6%, and General Mills CEO Jeff Harmening is calling the impact “lasting.” Food companies that haven’t started reformulating are already behind.
• 🤝 CPG M&A reflects a market split in two: Growth is diverging sharply between companies with portfolio discipline and those still caught in a volume-and-margin squeeze with no clear path out.

💰 Big Food’s turnaround plays are getting very specific

Broad strategy gives way to operational precision:

• Kraft Heinz is betting its $600M reinvestment on a blueprint-driven model, using standardized operational playbooks to reduce SKU complexity, improve execution consistency across plants, and eliminate the duplication that’s quietly drained margins for years. CEO Steve Cahillane has framed this not as a brand revival but as a manufacturing and go-to-market discipline problem, one the blueprints are designed to solve systematically. (Learn more)
• Big Food’s reinvention race is reshaping competitive positioning across the industry, with Nestlé, Unilever, Ferrero, Mars, PepsiCo, and Hershey each pursuing distinct recovery strategies — from supply chain overhaul to portfolio pruning to aggressive M&A. (Learn more)

Why it matters: The reinvention strategies taking shape now are structural, not cosmetic. Executives watching peers execute operational blueprints and win back shelf share should be asking which of their own complexity problems have gone unaddressed and at what ongoing cost.

⚖️ Regulatory stack grows taller

Three fronts are active simultaneously, each with a different timeline:

• The FDA’s updated “healthy” definition is now a supply chain problem, not just an R&D one. With the rule in effect since February 25, 2025 and full compliance required by 2028, early movers are locking in compliant ingredients (whole grains, specialty fibers, plant proteins), while late adopters face tightening supplier capacity, premium pricing, and compressed timelines. (Learn more)
• California is tightening food ingredient oversight, with implications that extend well beyond state lines. Multinationals rarely reformulate for one geography alone, meaning a California compliance requirement often becomes a de facto national standard, and eventually a global one. (Learn more)
• FSMA 204’s compliance window officially resets to July 20, 2028, and the FDA has clarified digital traceability expectations, finalized new exemptions (including Grade A cottage cheese), and released updated implementation resources. The extended deadline does not change the rule’s requirements; it changes the consequences of not moving now. (Learn more)

Why it matters: Three regulatory clocks are running at once, each demanding different internal resources. Companies managing these in parallel with lean teams face real execution risk, particularly if the “healthy” reformulation work competes with FSMA 204 data infrastructure investment for the same budget dollars.

⛓️ Tariff certainty lasted about 96 hours

The Supreme Court ruling created relief that evaporated almost immediately:

• On February 20, the Supreme Court struck down IEEPA tariffs 6-3, ruling the Act does not authorize the president to impose tariffs, as taxation power belongs to Congress. Markets briefly rallied. Hours later, the president signed a 10% global tariff under Section 122 of the Trade Act of 1974. The effective U.S. tariff rate went from 13.7% to about 8%, still double the former baseline of ~3%. Potential refunds on past IEEPA tariffs could reach $175 billion, though the court did not mandate the process. (Learn more)
• McCormick’s experience signals what’s coming for the broader industry: tariffs added $70 million in gross costs last year and are projected to add $50 million more this year. CEO Brendan Foley described September price actions as “surgical” but confirmed more increases are coming in February. Analysts say McCormick is not an outlier, but a preview of the industry-wide repricing wave building across ingredient-heavy categories. (Learn more)

Why it matters: The Supreme Court ruling did not end tariff uncertainty; it restructured it. Procurement and pricing teams that exhaled last week should be modeling the Section 122 scenario alongside whatever trade authority Congress may legislate next. The era of absorbing tariff costs without passing them through is over.

🤖 AI keeps hitting the same wall

The technology works. The data infrastructure doesn’t:

• For mid-sized food processors, AI adoption fails due to fragmented legacy data systems (ERPs, MES, spreadsheets) that prevent reliable data standardization. Bolting AI onto this disconnected environment accelerates dysfunction, not operations. The fix is prioritizing the “boring” work: standardizing data, creating a single source of truth, and contextualizing metrics before implementing AI. (Learn more)
• The 4-stage integration gap is the operational bottleneck most manufacturers aren’t naming clearly: data collection, data standardization, system connectivity, and decision intelligence must all be functional before AI investment pays off. Companies skipping stages to chase headline ROI are setting up expensive failures. (Learn more)

Why it matters: Mid-sized manufacturers face the same competitive pressures as their Fortune 500 counterparts but with a fraction of the IT budget. The companies getting AI right in this tier aren’t the ones with the most sophisticated tools; they’re the ones who invested in data discipline first.

🏪 GLP-1 is now a portfolio strategy problem

The window for a “wait and see” approach has closed:

• GLP-1 medications are used by roughly one in eight U.S. adults, with over half eligible. Cornell research shows a 6% drop in grocery spending by these households. General Mills CEO Jeff Harmening noted the “lasting influence” of anti-obesity drugs on the food market. General Mills is responding with smaller pack sizes and high-protein products such as Honey Nut Cheerios Protein and Ghost nutrition bars. (Learn more)
• The formulation response to GLP-1 demand is getting more specific: manufacturers are under pressure to pack more protein, fiber, vitamins, and minerals into smaller portions while maintaining taste, texture, and clean-label credentials. The challenge isn’t knowing what consumers want; it’s reformulating without sacrificing sensory performance or shelf life. Companies that crack this equation first will own the “GLP-1 premium” segment. (Learn more)

Why it matters: GLP-1 adoption is compressing volumes in snacks, sweet bakery, and processed categories that generate high margins. The companies winning in this environment are treating it as a product innovation mandate, not a marketing problem. And building the formulation capabilities to support it now.

🤝 CPG: A tale of two recoveries

The market is splitting into winners and everyone else:

• CPG is operating in two distinct cycles simultaneously: companies with pricing power, operational efficiency, and differentiated portfolios are posting modest growth; those without are stuck in a volume-and-margin squeeze with no obvious catalyst for recovery. The divergence reflects structural differences in portfolio quality and operational discipline that short-term market conditions can’t fix. (Learn more)
• Ingredion is doubling down on clean label and private label ingredient solutions, positioning itself to capture demand from manufacturers racing to reformulate for the FDA’s “healthy” definition and clean-label consumer expectations. The move reflects a broader pattern: ingredient suppliers with compliant, functional alternatives are gaining significant leverage as manufacturers scramble for compliant inputs ahead of 2028. (Learn more)

Why it matters: Portfolio quality and supply chain discipline now determine which side of the recovery you’re on. For executives, the strategic question is whether the right categories, capabilities, and supplier relationships are in place to execute when the cycle turns.

The Food Exec Brief provides weekly insights for food and beverage manufacturing leaders and publishes every Friday. Want to get essential food industry news delivered to your inbox? Sign up for our weekly and daily newsletters.